Tirzepatide and semaglutide are both injectable GLP-1 medications used for weight loss. They work in similar ways but are not the same drug. Tirzepatide activates two hormone receptors (GLP-1 and GIP); semaglutide activates one (GLP-1 only). In head-to-head clinical trials, tirzepatide has produced more weight loss on average — but semaglutide has a longer track record and may be a better fit for some people.
The right choice depends on your goals, side effect tolerance, budget, and medical history.
Mechanism. Tirzepatide: dual — GLP-1 plus GIP. Semaglutide: single — GLP-1 only.
Frequency. Both are once weekly injections.
Average weight loss at maximum dose (clinical trials). Tirzepatide: ~20-22% of body weight at 15mg. Semaglutide: ~15% of body weight at 2.4mg.
Dose range. Tirzepatide: 2.5mg to 15mg. Semaglutide: 0.25mg to 2.4mg.
Common side effects. Both share the same profile: nausea, constipation, fatigue.
Track record. Tirzepatide: approved 2022 (Mounjaro), 2023 (Zepbound). Semaglutide: approved 2017 (Ozempic), 2021 (Wegovy).
Brand names. Tirzepatide: Mounjaro, Zepbound. Semaglutide: Ozempic, Wegovy, Rybelsus.
Both drugs mimic gut hormones that affect appetite and blood sugar. The mechanism difference matters.
Semaglutide targets one receptor: GLP-1. It reduces appetite, slows gastric emptying, and improves insulin response. It was the first weekly GLP-1 medication to reach widespread use for weight loss.
Tirzepatide targets two receptors: GLP-1 and GIP. The GIP component is what makes tirzepatide different. GIP appears to enhance how fat cells store and release energy, may reduce nausea compared to GLP-1 alone, and supports stronger weight loss when combined with GLP-1 activity.
For a deeper breakdown, see how tirzepatide works for weight loss.
In a head-to-head clinical trial (SURMOUNT-5), tirzepatide produced significantly more weight loss than semaglutide at comparable doses.
Averages from the major weight loss trials:
Tirzepatide (SURMOUNT-1): ~20-22% body weight at 15mg over 72 weeks.
Semaglutide (STEP trials): ~15% body weight at 2.4mg over 68 weeks.
On paper, tirzepatide wins on average weight loss. But these are averages — individual results vary widely. Some people lose more on semaglutide than tirzepatide. The numbers also don't account for what you'll actually tolerate or stay on long-term.
Both medications have similar side effect profiles — mostly digestive (nausea, constipation, occasional diarrhea, fatigue). The differences are subtle:
Tirzepatide: Many patients report slightly milder nausea than on semaglutide. The GIP component may be why. But because tirzepatide reaches higher absolute doses (15mg vs 2.4mg), some people experience more digestive side effects overall.
Semaglutide: Has the longer track record for tolerance data. Nausea can be more pronounced for some people, particularly during dose increases.
For both, side effects are usually strongest in the first 4-8 weeks and fade as your body adapts. Our guide to managing GLP-1 side effects covers what helps.
Brand-name versions of both drugs cost roughly $1,000-$1,300 per month without insurance. Mounjaro/Zepbound and Ozempic/Wegovy are in a similar price range.
Compounded versions — prescribed by a licensed provider and produced by a licensed compounding pharmacy — are significantly more affordable. Belle's compounded semaglutide is available in 1mo, 3mo, and 6mo plans. Compounded tirzepatide is available in 3mo and 6mo plans.
Cost shouldn't be the only factor, but for many people, compounded options make ongoing treatment realistic. We break down the full picture in compounded vs brand-name GLP-1 cost.
Tirzepatide may be a better fit if you:
• Want the strongest weight loss effect on average
• Have more weight to lose
• Have type 2 diabetes (both work, but tirzepatide may have slight edge on blood sugar)
• Want a newer dual-mechanism approach
• Tolerate higher doses well
Semaglutide may be a better fit if you:
• Prefer a medication with a longer real-world track record
• Have a lower goal weight loss target (5-15% rather than 20%+)
• Want a more conservative starting option
• Have responded well to single-mechanism GLP-1 medications in the past
This isn't an either/or for life. Some people start on semaglutide and switch to tirzepatide later. Some do the reverse. Your provider can help you reassess at any point.
Switching between GLP-1 medications is common. Some people switch because of:
Plateau. Weight loss has stalled on one medication and the other might restart progress.
Side effects. One medication has been better tolerated than the other.
Cost or availability. One option has become more accessible.
If you switch, you'll restart at a low dose and titrate up again. Don't try to match doses between the two medications — they're not directly interchangeable. Your provider will design the transition.
Is tirzepatide always better than semaglutide?
On average, tirzepatide produces more weight loss. But "better" depends on your goals, tolerance, and individual response. Some people respond beautifully to semaglutide and find tirzepatide less comfortable.
Can you take both at the same time?
No. They work on overlapping pathways and combining them increases side effects without proven benefit.
Which one has fewer side effects?
It's individual. Many people find tirzepatide slightly easier on nausea due to the GIP component. Others tolerate semaglutide better. The starting doses for both are designed to minimize side effects.
Does tirzepatide work faster?
Both produce noticeable appetite changes within the first week or two. Tirzepatide may produce faster weight loss at comparable points in titration, but both build over months.
Which is better for type 2 diabetes?
Both improve blood sugar control. Tirzepatide showed slight edge in clinical trials for A1c reduction. Your provider will factor this in if you have diabetes — see our guide to GLP-1 medications and type 2 diabetes.
Are the compounded versions just as effective?
Compounded versions use the same active ingredient as brand-name drugs. When sourced from licensed compounding pharmacies and prescribed by licensed providers, they're designed to match the pharmacokinetics of brand-name versions. Our guide to how compounded GLP-1 medications are made covers this in detail.
The honest answer: both are effective. The choice depends on your specific situation, and a licensed provider is the right person to help you make it.
Belle's licensed providers prescribe both tirzepatide and semaglutide, and can switch you between the two if needed. Complete your medical intake form to discuss which is right for you.
All Belle programs require a licensed provider consultation and prescription. Compounded medications are not FDA-approved finished drug products. This content is for informational purposes and does not constitute medical advice.
